The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

This looked at patients with transplant-eligible newly diagnosed multiple myeloma ... survival [PFS], as well as overall ...

Overall response rate (ORR): percentage ... control and longer survival, he explained. Fung is the chair of the Department of Bone Marrow Transplant and Cellular Therapies and director of the Multiple ...

Are an adult with relapsed or refractory multiple myeloma ... cancer shrank (partial response) or disappeared completely (complete response) after getting Tecvayli. This is called overall ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Sharda Sinha's battle with Multiple Myeloma highlights the disease's dangers. Learn about its impact and significance.- Watch ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant ... Study findings were reported in the journal Bone Marrow ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Multiple myeloma ... bone disease had a significantly worse outlook than people without these symptoms. The development of anemia or kidney failure wasn’t associated with a worsened survival rate.

Here she explains just what are these remnants of cancer that remain ... through blood-based testing or bone marrow–based testing. Historically, we evaluated myeloma through monoclonal proteins ...